BRCA-associated protein 1 mutant cholangiocarcinoma: An aggressive disease subtype

Journal of Gastrointestinal Oncology

Volumn 7, Issue 4, 2016, Pages 556-561

  Al Shamsi, Humaid O ^a   Anand, Deepa ^a   Shroff, Rachna T ^a   Jain, Apurva ^a   Zuo, Mingxin ^a   Conrad, Claudius ^a   Vauthey, Jean Nicolas ^a   Javle, Milind M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BAP1 mutant cholangiocarcinoma; Cisplatin; Foundation Medicine; Gemcitabine; Next generation sequencing (NGS)

Indexed keywords

CAPECITABINE; CISPLATIN; ERLOTINIB; GEMCITABINE;

ADULT; AGED; ARTICLE; BAP1 GENE; BILE DUCT CARCINOMA; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; GENE; GENE MUTATION; GENERAL ASPECTS OF DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDICAL DECISION MAKING; MIDDLE AGED; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PERITONEUM METASTASIS; PHENOTYPE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TIME TO PROGRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME; VERY ELDERLY;

EID: 84995743408     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.21037/jgo.2016.03.05     Document Type: Article

References (19)

1. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008;12:131-50, ix.
2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25.
3. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472-7.
4. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospitalbased case-control study. Am J Gastroenterol 2007;102:1016-21.
5. Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9:e115383.
6. Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer 2013;13:153-9.
7. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology 2013;45:116-26.
8. Gnirke A, Melnikov A, Maguire J, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 2009;27:182-9.
9. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
10. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078-9.
11. American Joint Committee on Cancer Staging Manual, Seventh Edition. New York: Springer, 2010. Available online: https://cancerstaging.org
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
13. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
14. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
15. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
16. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012;18:408-16.
17. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45:1470-3.
18. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009;69:1911-34.
19. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-5.